Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2022; 14(4): 766-777
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.766
Impact of liver cirrhosis on ST-elevation myocardial infarction related shock and interventional management, a nationwide analysis
Sophia Haroon Dar, Mehek Rahim, Davood K Hosseini, Khurram Sarfraz
Sophia Haroon Dar, Mehek Rahim, Davood K Hosseini, Khurram Sarfraz, Internal Medicine, Hackensack University Medical Center, Hackensack, NJ 07601, United States
Author contributions: Dar SH decided topic, designed study, completed the analysis, wrote, edited, and finalized paper; Rahim M participated in editing and finalizing the paper; Hoesseini DK and Sarfraz K participated in writing the initial draft.
Institutional review board statement: This is a retrospective review on a national database and did not require IRB approval.
Informed consent statement: This project was done on a large database national inpatient sample and did not require individual patient consent as it is a publicly available database.
Conflict-of-interest statement: There are no known conflicts of interest.
Data sharing statement: No individual patient identifiers are present in the national database. Therefore, no individual can be traced.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sophia Haroon Dar, MD, Doctor, Internal Medicine, Hackensack University Medical Center, 30 Prospect Avenue Department of Internal Medicine Hackensack University Medical Center Hackensack NJ, 70601, Hackensack, NJ 07601, United States. sophia.dar@hmhn.org
Received: November 8, 2021
Peer-review started: November 8, 2021
First decision: December 12, 2021
Revised: January 4, 2022
Accepted: March 7, 2022
Article in press: March 7, 2022
Published online: April 27, 2022
Processing time: 164 Days and 12.8 Hours
ARTICLE HIGHLIGHTS
Research background

ST-Elevation myocardial infarction (STEMI) remains a significant cause of morbidity and mortality globally. A particularly susceptible population are patients with liver cirrhosis.

Research motivation

This study aims to find what factors predicted morbidity and mortality in patients with liver cirrhosis that may need to undergo interventional management for STEMI related cardiogenic shock.

Research objectives

We aim to identify predictors of morbidity and mortality in patient with liver cirrhosis that undergo interventional management for STEMI related cardiogenic shock. We aim to find the effect of liver cirrhosis on mortality, length of stay, and hospital costs in patients with STEMI related cardiogenic shock.

Research methods

We conducted a retrospective review on the national inpatient sample 2017. Using the student t-test and propensity-matched multivariate logistic regression, we were able to find the P value and odds of mortality.

Research results

We find that patients with liver cirrhosis have significantly higher morbidity and mortality rates than those without liver cirrhosis. They are also susceptible to adverse outcomes when undergoing interventional management.

Research conclusions

Physicians must optimize patients with liver cirrhosis before any interventional procedure. Patients with mild cirrhosis seemed to have better outcomes than patients with moderate-severe liver cirrhosis.

Research perspectives

This research will help build the framework for future studies to study this topic further. The goal would be to identify a scoring system that would allow physicians to ascertain which patients would be safely able to undergo interventional management and which would not. As of now, it is mostly under clinical judgment.